TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00511459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 386 Placebo
Description: AMG 386 Placebo \[blinded\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: AMG 386 3mg/kg IV QW \[blinded\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg IV Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg IV Q2W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg IV Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: AMG 386 10mg/kg IV QW \[Open-Label\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: AMG 386 10mg/kg IV QW \[blinded\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 90mg/m2 IV QW (3 on/1 0ff)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 90mg/m2 IV QW (3 on/1 0ff)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 90mg/m2 IV QW (3 on/1 0ff)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 90mg/m2 IV QW (3 on/1 0ff)
Study: NCT04374019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin:~Days 1-2: Weight \< 75kg: 4 tabs (12 mg total daily dose) Days 1-2: Weight \> 75kg: 5 tabs (15 mg total daily dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat Mesilate
Description: Days 1-14: 2 tab TID after a meal (600 mg total daily dose)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artemesia annua
Description: Days 1-14: tea or coffee pod TID (1350 mg total daily dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Days 1-14:
Study: NCT04053517

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Medical chart is reviewed

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05018949

Intervention type: PROCEDURE
Intervention: Lower limb angioplasty
Description: Patients who have undergone LL angioplasty are enrolled in study for a medical records review.
Study: NCT00761618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrapleural catheter (IPC) drained
Description: IPC drained daily (Group 1) or 3 times per week (Group 2)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrapleural catheter (IPC) drained
Description: IPC drained daily (Group 1) or 3 times per week (Group 2)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPC Placement
Description: IPC placed in chest cavity to drain excess fluid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPC Placement
Description: IPC placed in chest cavity to drain excess fluid

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chest X-Ray
Description: Chest X-Rays at 3 and 6 month follow up visits

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chest X-Ray
Description: Chest X-Rays at 3 and 6 month follow up visits
Study: NCT02828592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 IV QD x 5 days (Days -6 to -2)
Study: NCT04138849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-877 single dose
Description: Oral capsule, single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-877 single dose
Description: Oral capsule, single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-877 single dose
Description: Oral capsule, single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single dose
Description: Oral capsule, single dose.
Study: NCT06754254

Intervention type: DIAGNOSTIC_TEST
Intervention: blood biomarkers from the internal jugular vein
Description: blood biomarkers (Aβ42/40, p-tau217, p-tau181, NFL, GFAP, etc.) from the internal jugular vein

Intervention type: DIAGNOSTIC_TEST
Intervention: blood biomarkers from the internal jugular vein
Description: blood biomarkers (Aβ42/40, p-tau217, p-tau181, NFL, GFAP, etc.) from the internal jugular vein
Study: NCT04468971

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CK0802
Description: Cryopreserved, off the shelf, cord blood derived T regulatory cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CK0802
Description: Cryopreserved, off the shelf, cord blood derived T regulatory cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Expicient
Study: NCT02367053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP4207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Study: NCT04064229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ivWatch Model 400 with SmartTouch Sensor
Description: The ivWatch Model 400 with SmartTouch Sensor monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ivWatch Model 400 with Fiber Optic Sensor
Description: The ivWatch Model 400 with Fiber Optic Sensor monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
Study: NCT00836927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus Tablet
Description: Ridaforolimus 10 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus Tablet
Description: Ridaforolimus 10 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus Tablet
Description: Ridaforolimus 10 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus Tablet
Description: Ridaforolimus 10 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus Tablet
Description: Ridaforolimus 10 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus Intravenous (IV) Infusion
Description: Ridaforolimus IV infusion administered once daily for 5 days every 2 weeks in a 28-day cycle (two 2-week courses equals 1 cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus Intravenous (IV) Infusion
Description: Ridaforolimus IV infusion administered once daily for 5 days every 2 weeks in a 28-day cycle (two 2-week courses equals 1 cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus Intravenous (IV) Infusion
Description: Ridaforolimus IV infusion administered once daily for 5 days every 2 weeks in a 28-day cycle (two 2-week courses equals 1 cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus Intravenous (IV) Infusion
Description: Ridaforolimus IV infusion administered once daily for 5 days every 2 weeks in a 28-day cycle (two 2-week courses equals 1 cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus Intravenous (IV) Infusion
Description: Ridaforolimus IV infusion administered once daily for 5 days every 2 weeks in a 28-day cycle (two 2-week courses equals 1 cycle).
Study: NCT00490061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1500 mg po daily orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy (radiation)
Description: Standard of Care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G.E. Healthcare 1.5T MR, systems revision 12.0 M5
Description: Standard of Care, used to deliver IMRT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCE-MRI
Description: A subset of patients received imaging before and after Lapatinib loading, prior to starting radiotherapy.
Study: NCT04399135

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Orthopantomogram X-ray view
Description: taking an X-ray to determine bone loss level and attachment loss level for periodontitis classification

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Orthopantomogram X-ray view
Description: taking an X-ray to determine bone loss level and attachment loss level for periodontitis classification

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Endo-Ice
Description: Included teeth will be dried with 4x4 gauze then tested with a cold test using Endo-Ice.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Endo-Ice
Description: Included teeth will be dried with 4x4 gauze then tested with a cold test using Endo-Ice.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Electric Pulp Tester (EPT)
Description: Included teeth will be dried with 4x4 gauze then tested with an Electric test using electric pulp tester (EPT).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Electric Pulp Tester (EPT)
Description: Included teeth will be dried with 4x4 gauze then tested with an Electric test using electric pulp tester (EPT).
Study: NCT06752837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tornado rotary system
Description: In arm one, stainless steel tornado files works by high-speed rotation that influences the fluid dynamics within the canal and improves irrigation efficiency. Canals are finished with a file having a 4% taper and an apical diameter of 0.25 mm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WaveOne rotary system
Description: In arm two, WaveOne system is a single reciprocating file system with a heat-treated NiTi Memory Wire (M Wire).It has a taper of 0.08 in apical 3 mm, with a tip diameter of 0.25 mm. in a torque control endodontic handpiece (X smart plus with reciprocation mode)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneShape rotary system
Description: In arm three, OneShape system utilizes a conventional, continuous rotational motion. It has asymmetric cross-sectional geometry, and traveling waves of motion that are produced along the file's active region. It has a single constant taper of 0.06 and a tip size of 25 with distinct cross-sectional designs along the whole length of the working parts

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cone beam computed tomography
Description: A post-operative CBCT image was obtained and compared to the pre-operative one to assess the impact of canal preparation of each file on the periapical lesion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cone beam computed tomography
Description: A post-operative CBCT image was obtained and compared to the pre-operative one to assess the impact of canal preparation of each file on the periapical lesion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cone beam computed tomography
Description: A post-operative CBCT image was obtained and compared to the pre-operative one to assess the impact of canal preparation of each file on the periapical lesion.
Study: NCT00766636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Arm A:~1000 mg/M\^2 given intravenously over 100 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day.~Arm B:~400 mg/M\^2 given intravenously over 40 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Arm A:~1000 mg/M\^2 given intravenously over 100 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day.~Arm B:~400 mg/M\^2 given intravenously over 40 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day.
Study: NCT02828592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14.5 mg/kg/day IV x 2 doses (Days -6 \& -5)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 300 cGy x1 dose (Day -1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit ATG
Description: 1.5 mg/kg/day x 3 days (Days -3 to -1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Post-transplant: 50 mg/kg IV QD (Day +3 to +4)
Study: NCT01885377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific exercise group
Description: A program where exercise load is individually adjusted and the exercises progressed during a 3 month period. The 'pain monitoring model' were used to find the individual resistance. Several exercises are performed eccentrically in order to load more. Initially the exercises were PT-tutored every week and then every other week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control exercise group
Description: A program with movements to maintain flexibility in the neck and shoulder muscles. Initially PT-tutored every week and then every other week.
Study: NCT01903538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (tDCS)
Description: Cathodal transcranial direct current stimulation (tDCS) 20min, 1mA, F3 (EEG 10/20), reference right M. deltoideus

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: Sham transcranial direct current stimulation (tDCS) 40s, 1mA, F3 (EEG 10/20), reference right M. deltoideus
Study: NCT04368429

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine)
Description: Pharmaceutical form: Liquid solution Route of administration: IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: Pharmaceutical form: Liquid solution Route of administration: IM
Study: NCT02498483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Infants will receive 15 mg/kg of acetaminophen.
Study: NCT00222534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02247609

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR T cells
Description: Autologous 4th generation withdrawable lentiviral-transduced anti-CD19-CAR T cells
Study: NCT01746693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer
Description: retinal vessel diameter, retinal oxygen saturation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer
Description: retinal vessel diameter, retinal oxygen saturation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer
Description: retinal vessel diameter, retinal oxygen saturation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser Doppler Velocimetry
Description: retinal blood flow velocity, retinal blood flow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser Doppler Velocimetry
Description: retinal blood flow velocity, retinal blood flow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser Doppler Velocimetry
Description: retinal blood flow velocity, retinal blood flow

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7-Tesla MRI
Description: High resolution functional and anatomical imaging of the visual pathway

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7-Tesla MRI
Description: High resolution functional and anatomical imaging of the visual pathway

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7-Tesla MRI
Description: High resolution functional and anatomical imaging of the visual pathway

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pattern electroretinography
Description: inner retinal function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pattern electroretinography
Description: inner retinal function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pattern electroretinography
Description: inner retinal function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fourier domain optical coherence tomography
Description: Blood flow in retina.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fourier domain optical coherence tomography
Description: Blood flow in retina.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fourier domain optical coherence tomography
Description: Blood flow in retina.
Study: NCT03078270

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: botulinum toxin A
Description: Single treatment visit for 5 injections of botulinum toxin A, 40 units (for females) and 50 units (for males)/

Intervention type: DRUG
Group type: OTHER
Intervention: botulinum toxin A
Description: Single treatment visit for 5 injections of botulinum toxin A, 40 units (for females) and 50 units (for males)/

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single treatment visit for 5 injections of normal saline
Study: NCT00766636

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 1 time each day for 5 days in a row for 5 1/2 weeks starting on Day 1 for a total of 50.4 Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 100 mg daily by mouth on days 1-42.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 100 mg daily by mouth on days 1-42.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical removal of the pancreas and duodenum
Study: NCT03704766

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Synovial Leukocyte Esterase Test Strips
Description: These test strips will be tested at the hospital where the patient is being seen, a few drops of synovial fluid will be used on the strip.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Synovial Leukocyte Esterase Test Strips
Description: These test strips will be tested at the hospital where the patient is being seen, a few drops of synovial fluid will be used on the strip.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Synovial PCR for Kingella kingae
Description: In participants \< 8 years old, a sample of synovial fluid will be tested for Kingella kingae using PCR.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Synovial PCR for Kingella kingae
Description: In participants \< 8 years old, a sample of synovial fluid will be tested for Kingella kingae using PCR.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum Cell count + differential (CBC)
Description: A blood test performed at the hospital.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum Cell count + differential (CBC)
Description: A blood test performed at the hospital.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum erythrocyte sedimentation rate (ESR)
Description: A blood test performed at the hospital.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum erythrocyte sedimentation rate (ESR)
Description: A blood test performed at the hospital.
Study: NCT00766636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical removal of the pancreas and duodenum
Study: NCT00452582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil (Viagra)
Description: Dose escalation (one of the following): 25 mg daily for 2 weeks, 50 mg daily for 2 weeks, 75 mg daily for 2 weeks, 50 mg twice daily for two weeks, 50 mg AM and 75 mg PM for 2 weeks, 75 mg twice daily for 2 weeks, 75 mg in AM and 100 mg in PM for 2 weeks, 100 mg twice daily for 2 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Physical therapy, occupational therapy, speech therapy
Study: NCT00511914

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cTIV
Description: One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cTIV
Description: One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle
Study: NCT00952159

Intervention type: BIOLOGICAL
Intervention: Monitoring seric concentrations of O-demethyl-tramadol and tramadol
Description: The first aim of this study is the validation of monitoring seric concentrations of O-demethyl-tramadol and tramadol to make the ratio in order to detect CYP2D6 poor metabolizers in therapeutic situation, comparing the result with genotyping. The finding of a poor metabolizer status in a patient will make the choice of analgesic drugs easier, avoiding tramadol and codeine. The final objective of this research is to be able to determine the CYP2D6 phenotype in a patient treated by tramadol without a good analgesia. By a single take of blood and a rapid response, this method should be liked to improve pain management. Furthermore, CYP2D6 phenotyping is interesting for the patient because many other drugs depend on this way of metabolism.

Intervention type: BIOLOGICAL
Intervention: Monitoring seric concentrations of O-demethyl-tramadol and tramadol
Description: The first aim of this study is the validation of monitoring seric concentrations of O-demethyl-tramadol and tramadol to make the ratio in order to detect CYP2D6 poor metabolizers in therapeutic situation, comparing the result with genotyping. The finding of a poor metabolizer status in a patient will make the choice of analgesic drugs easier, avoiding tramadol and codeine. The final objective of this research is to be able to determine the CYP2D6 phenotype in a patient treated by tramadol without a good analgesia. By a single take of blood and a rapid response, this method should be liked to improve pain management. Furthermore, CYP2D6 phenotyping is interesting for the patient because many other drugs depend on this way of metabolism.
Study: NCT02638584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 10mg 2tablets once a day(1 times / day), before breakfast